Myeloid Mimicry Enables Kidney Tumors to Resist Immunotherapy and Worsen Rapidly, Study Finds

Myeloid mimicry enables kidney tumors to resist immunotherapy and worsen rapidly, study finds

Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism called "myeloid mimicry" to hide from the immune system and promote disease hyperprogression after immunotherapy, highlighting specific targets that overcome treatment resistance in preclinical models.

OGT SureSeq Myeloid MRD Plus NGS Panel

OGT has launched its next-generation sequencing (NGS) panel for measurable residual disease (MRD): the SureSeq Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of expertise in hybrid capture technology, the panel detects ultralow-frequency variants in key MRD-associated biomarkers in acute myeloid leukaemia (AML). This means users can obtain detailed genomic information, to provide an earlier and more complete picture of their sample’s …

Blocking Myeloid Mimicry Pathway Enhances Immunotherapy in RMC

Researchers at the University of Texas MD Anderson Cancer Center have discovered that renal medullary carcinoma (RMC) cells use a process called “myeloid mimicry” to evade the immune system and promote rapid disease progression following immunotherapy treatment. This discovery, published in Nature Communications, came about after a Phase II clinical trial testing a combination therapy of two immune checkpoint inhibitors (ICIs) was halted after a…